[go: up one dir, main page]

WO1990011779A1 - Heteroconjugues - Google Patents

Heteroconjugues Download PDF

Info

Publication number
WO1990011779A1
WO1990011779A1 PCT/GB1990/000476 GB9000476W WO9011779A1 WO 1990011779 A1 WO1990011779 A1 WO 1990011779A1 GB 9000476 W GB9000476 W GB 9000476W WO 9011779 A1 WO9011779 A1 WO 9011779A1
Authority
WO
WIPO (PCT)
Prior art keywords
antigen
antibody
tumour
patient
conjugate according
Prior art date
Application number
PCT/GB1990/000476
Other languages
English (en)
Inventor
Peter Julius Lachmann
Original Assignee
Medical Research Council
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medical Research Council filed Critical Medical Research Council
Publication of WO1990011779A1 publication Critical patent/WO1990011779A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/04—Mycobacterium, e.g. Mycobacterium tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/44—Antibodies bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6056—Antibodies
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Definitions

  • the present invention relates to novel targetting agents and to their use in the treatment of cancers. Radio- and chemotherapy are now well established as cancer treatments, as is surgery, for clearly defined tumours. However these techniques are less effective at destroying small lesions due to metastasis and, with surgery, there is always a risk of leaving behind small areas of cancerous tissue.
  • the present invention is particularly concerned with providing a means to clear up such small pockets of cancerous cells and is therefore considered mainly as an adjunct to the already established therapeutic and surgical techniques.
  • the invention aims to recruit aspects of the patient's own immune system and to target this against the tumour cells.
  • the present invention in one aspect provides a method for the treatment of the human or animal body comprising administering an effective, non-toxic amount of a targetting agent which is a conjugate of an antigen and an antibody, or fragments thereof, the antigen being selected such that the patient already has immunity to the antigen and the antibody being selected to bind specifically to the tumour cells.
  • a targetting agent which is a conjugate of an antigen and an antibody, or fragments thereof, the antigen being selected such that the patient already has immunity to the antigen and the antibody being selected to bind specifically to the tumour cells.
  • Figs, la & lb show the clone 3-PPD conjugate mediated lysis of C3 coated MC6A tumour cells in cytotoxicity assays.
  • Figs. 2a & 2b show the MM2-9B6-PPD conjugate mediated lysis of B16-F10 tumour cells in cytotoxicity assays.
  • Figs. 3a & 3b show the tumour cytostasis mediated by clone supernatant.
  • Figs. 4a & 4b show lymphokine assays.
  • the antigen may be any antigen to which the patient has previously been exposed, or any antigen which cross-reacts with lymphocytes in the patient's blood.
  • suitable antigens include those of the childhood illnesses such as measles, chickenpox or mumps and other antigens to which the population in general is likely to have induced immunity, for instance, tetanus, typhoid and tuberculosis. The latter is particularly relevant to the present invention as the vast majority of the population have been immunised using BCG vaccine against Mvcoplasma tuberculosis. the cross-reacting PPD (purified protein derivative) from M.
  • PPD purified protein derivative
  • tuberculosis may be used in the present method and is particularly preferred because of the very strong immune reaction which it elicits. Fragments of such antigens may also be used in the invention provided that they retain the epitope which will be recognised by the patient's immune system. In the case of PPD, which consists of a number of different polypeptide sub-units, any antigenic sub-unit or indeed any antigenic domain of one of the sub-units, may be used as the antigen.
  • the antibody used in the conjugate may be any antibody or fragment thereof which retains an antigen-binding site, such as the Fab' fragment, which will bind specifically to the tumour cells to be destroyed.
  • tumour specific antigens are now known and others will be discovered in the future; antibodies, whether polyclonal or monoclonal (the latter are preferred) against such antigens may be used in the present invention.
  • Certain tumours do not express tumour-specific antigens but these may be targetted using antibodies against neo-antigens in bound components of complement, such as C3 which are often found to accumulate on the surface of those tumour cells which activate the alternative complement pathway.
  • Antibodies against C3 or other complement components may also be used when the conjugates of the invention are to be administered after conventional monoclonal antibody treatment of cancers.
  • tumour specific antibodies results in the tumour cells becoming covered first in the anti-tumour antibodies and then in complement which binds to the anti-tumour antibodies.
  • anti-complement antibodies it is preferred that they are directed against neo-antigenic sites, i.e, sites which are only formed or exposed once complement binding has occurred, in order that binding to unbound complement is avoided.
  • the antibodies should preferably be derived from antibody-producing cells of the same species as the patient or should be modified to mask or remove any species-specific determinants other than those of the same species as the patient.
  • the antigen (or fragment thereof) and antibody (or fragment thereof) may be coupled by any conventional method for covalently binding such materials.
  • linking groups may be bound to the antigen and to the antibody and the linking groups are then coupled together.
  • one linking group is formed using the reagent SMCC (succinimidyl4-(N-maleimidomethyl)cyclohexane-
  • Coupling techniques should be selected so as to avoid impairing either the antigenicity of the antigen or the affinity of the antibody for the tumour cells; where necessary the product may be fractionated to obtain quantities of effective conjugate.
  • the present invention also provides a conjugate comprising an antigen and an antibody, or fragments thereof, covalently coupled via linking groups. Processes for coupling the antigen and antibody to form such a conjugate form a further aspect of the invention.
  • the invention further provides such conjugates for use in a therapeutic method for the treatment of the human or animal body and the use of such conjugates in the manufacture of a medicament for use in the treatment of cancer.
  • the conjugates of the invention may be administered as such but are preferably administered as pharmaceutical compositions also comprising a pharmaceutically acceptable diluent or carrier.
  • Typical diluents and carriers include water for injection and other injection media.
  • compositions may be presented in unit or multi-dosage form.
  • the compositions may be presented in ready-to-use form or as a concentrate or dry powder for reconstitution, e.g. using water for injection, prior to use.
  • the compositions will generally be sterile and pyrogen free.
  • the compositions may also comprise accessory ingredients such as antibacterial and antifungal agents, buffers, salts, agents to adjust the tonicity of the composition, anti-oxidants, wetting agents and suspending agents to improve the solubilisation or suspension of the conjugates and analgesics or anaesthetics to reduce pain at the injection site.
  • conjugates and compositions of the invention will usually be administered by injection, preferably by the intravenous route, or by infusion. Where appropriate, injection or infusion directly into a tumour or lesion is also contemplated.
  • the dosage amounts will be depend on the patient- for instance body weight, age, sex and general state of health - the size, location and nature of the tumour and the rate of clearance of the agent as well as the antigenicity of the conjugate and the level of the patient's immunity to the antigen or fragment thereof.
  • the dosage of a conjugate of PPD and an antibody would be in the range of from 10 to 50 ⁇ g PPD per injection.
  • Dosage regimes also depend upon a number of factors including those outlined above.
  • the administration may take place over the period of several hours, possibly repeated daily, or may continue uninterrupted for days.
  • the conjugates are preferably administered either daily or at longer intervals, for instance of a few days. Administration may be repeated as necessary.
  • the conjugates of the invention will bind to the tumour cells by virtue of the interaction between the antibody part of the conjugate and the corresponding tumour specific antigen or complement component. This results in the tumour cells being labelled with the antigen part of the conjugate. This is then recognised by the cellular immune system of the patient leading to the development of a local delayed-type hypersensitivity (DTH) reaction with destructive effects against tumour cells, and possibly adjacent cells, effected by T helper cells and their secreted products. The generation of cytotoxic T cells should also be enhanced as a result.
  • DTH delayed-type hypersensitivity
  • Treatment involving the use of conjugates according to the invention may therefore involve testing samples of tissue or body fluid from the patient to identify a suitable antigen against which the patient has T-cell immunity and selection of a conjugate of such an antigen.
  • MAbs were used which were specific for a tumour associated antigen of CS7/BL6 melanomas, or for the human complement component C3d, which was fixed de novo to the surface of tumour cells.
  • the ability of the conjugate to induce PPD-specific T-cell activation, lymphokine secretion and tumour cell cytolysis/cytostatis in vivo was determined with a view to focusing a DTH response against selected tumour target in BCG immunized animals.
  • Effectors Synergistic non-adherant spleen cells from BCG immunized mice or a L3T4+, Lyt-, PPD reactive T-cell clone (PPD-MW1) .
  • MAb was covalently linked to PPD using the hetero- bifunctional cross linkers SPDP and SMCC.
  • Tumour cells were pretreated (45 mins, 4°C) with optimal concentrations of either MM2-9B6-PPD or Clone 3-PPD conjugates. Control cells were treated with equivalent concentrations of the MAbs or PPD alone. Tumour cells were then co-cultured with effectors for 16 hrs. at various E.T. ratios. Specific cytotoxicity was determined using a standard 51Cr release assay.
  • TNF Tumour necrosis factor alpha/beta
  • Clone PPD-MWl was activated by B16-F10 cells pretreated with MM2-9B6-PPD and TNF production determined using the TNF sensi .ti.ve cell li.ne L929. 51Cr labelled L929 cells were incubated with serially diluted control and activated clone supernatant for 16 hrs in the presence of actinomycin D. Susceptibility of the tumour targets to human recombinant TNF (rTNF) alpha was measured using a 16 hr
  • Control and MM2-9B6-PPD conjugate treated B16-F10 cells were injected SC into BCG immunized or normal C57/BL6 mice (3 x 10 5 cells/animal) . Tumours were excised on day 11 and weighed. Significance levels were determined using the Mann-Whitney U test.
  • Clone 3-PPD conjugate mediated significant levels of cytoxicity against C3 coated MC6A tumour cells using both immune spleen cells (Fig. la) and the clone (Fig. lb) at high E:T ratios. MAb or PPD alone did not increase cytotoxicity.
  • MM2-9B6-PPD conjugate failed to mediate significant levels of cytotoxicity against B16-F10 tumour cells when immune spleen cells were used as a source of effectors.
  • Fig 2a Marginal cytotoxicity above control levels was, however, evident when the PPD-reactive clone was used.
  • Tumour cells pretreated with MM2-9B6-PPD conjugate were able to stimulate clone PPD-MWl to produce significant levels of TNF alpha/beta (Fig 4a) .
  • Significant MAF activity at a supernatant titer of 1/32 was also found.
  • Susceptibility of the tumour lines of rTNF alpha correlated well with the levels of cytotoxicity observed in vitro with PPD-reactive T-cells (Figs, l & 2) .
  • MAb-PPD heteroconjugates specific for a tumour associated antigen, or a de novo fixed complement component can be used to focus PPD-specific T-cells onto tumour targets in vitro.
  • Heteroconjugate treated tumour cell targets activate PPD-specific T-cell clones, resulting in concomitant release of significant levels of TNF alpha/beta and MAF.
  • Susceptibility of the tumour targets to rTNF alpha correlated well with the levels of cytotoxicity achieved over 18 hours in vitro with PPD-specific T-cells.
  • the high levels of cytostatis achieved over 72 hours could not, however, be attributed solely to the activity of rTNF alpha and may reflect synergy between the TNF alpha/beta and MAF.
  • the activation of PPD-specific T-helper cells at sites of tumour growth in vivo may result in the recruitment of other tumourcidal effects, and ultimately induce a DTH response.
  • Heteroconjugates directed to complement components should further allow the activation of T-cells at sites of complement fixation, and this may be exploited to enhance the effectiveness of conventional MAb therapy.
  • MM2-9B6-PPD conjugate can give a significant reduction in the growth of B16-F10 cells in BCG immunised animals.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

L'invention concerne un conjugué antigène-anticorps, permettant le traitement d'une tumeur chez un patient, l'antigène étant un antigène contre lequel le patient est immunisé, et l'anticorps étant capable de lier spécifiquement les cellules de la tumeur.
PCT/GB1990/000476 1989-03-31 1990-03-30 Heteroconjugues WO1990011779A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB898907310A GB8907310D0 (en) 1989-03-31 1989-03-31 Heteroconjugates
GB8907310.0 1989-03-31

Publications (1)

Publication Number Publication Date
WO1990011779A1 true WO1990011779A1 (fr) 1990-10-18

Family

ID=10654268

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB1990/000476 WO1990011779A1 (fr) 1989-03-31 1990-03-30 Heteroconjugues

Country Status (2)

Country Link
GB (1) GB8907310D0 (fr)
WO (1) WO1990011779A1 (fr)

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LT3909B (lt) 1990-07-20 1996-04-25 Kabi Pharmacia Ab Nauji antikūnio-superantigeno konjugatai, jų gavimo būdas, ląstelės-taikinio ūžavimo būdas ir konjugatų panaudojimas farmacinėse kompozicijose
US5858363A (en) * 1990-07-20 1999-01-12 Pharmacia & Upjohn Ab Target specific antibody-superantigen conjugates and their preparation
WO2001054731A3 (fr) * 2000-01-28 2002-12-12 Univ Singapore Nouveaux ligands et procedes de preparation correspondants
EP0510949B2 (fr) † 1991-04-23 2003-04-02 Sangstat Medical Corporation Conjugués cytomodulateurs constants de pair liants spécifiques
US7153977B2 (en) 2000-01-28 2006-12-26 National University Of Singapore Ligands and methods for preparing same
US8105608B2 (en) 2000-03-31 2012-01-31 Purdue Research Foundation Method of treatment using ligand-immunogen conjugates
WO2015105973A1 (fr) * 2014-01-08 2015-07-16 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Anticorps ciblant une protéine c3d du complément déposée sur une surface cellulaire, et utilisation de celui-ci

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0245078A2 (fr) * 1986-05-06 1987-11-11 Connaught Laboratories Limited Augmentation de l'immunogénicité d'antigènes
EP0324625A1 (fr) * 1988-01-12 1989-07-19 Bunge (Australia) Proprietary Limited Conjuqué anticorps-antigène
EP0336405A2 (fr) * 1988-04-08 1989-10-11 Takeda Chemical Industries, Ltd. Complexes protéiniques contre le cancer humain, leur préparation et leur utilisation

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0245078A2 (fr) * 1986-05-06 1987-11-11 Connaught Laboratories Limited Augmentation de l'immunogénicité d'antigènes
EP0324625A1 (fr) * 1988-01-12 1989-07-19 Bunge (Australia) Proprietary Limited Conjuqué anticorps-antigène
EP0336405A2 (fr) * 1988-04-08 1989-10-11 Takeda Chemical Industries, Ltd. Complexes protéiniques contre le cancer humain, leur préparation et leur utilisation

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Experientia, Volume XVIII, No. 12, 15 December 1962, L. FORRO et al.: "A New Type of Antigen Induced by Chemical Linkage of Mycobacterium Tuberculosis and Y-Globulin", pages 553-554 *

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LT3909B (lt) 1990-07-20 1996-04-25 Kabi Pharmacia Ab Nauji antikūnio-superantigeno konjugatai, jų gavimo būdas, ląstelės-taikinio ūžavimo būdas ir konjugatų panaudojimas farmacinėse kompozicijose
US5858363A (en) * 1990-07-20 1999-01-12 Pharmacia & Upjohn Ab Target specific antibody-superantigen conjugates and their preparation
EP0510949B2 (fr) † 1991-04-23 2003-04-02 Sangstat Medical Corporation Conjugués cytomodulateurs constants de pair liants spécifiques
WO2001054731A3 (fr) * 2000-01-28 2002-12-12 Univ Singapore Nouveaux ligands et procedes de preparation correspondants
US7153977B2 (en) 2000-01-28 2006-12-26 National University Of Singapore Ligands and methods for preparing same
SG148022A1 (en) * 2000-01-28 2008-12-31 Univ Singapore Novel ligands and methods for preparing same
US8105608B2 (en) 2000-03-31 2012-01-31 Purdue Research Foundation Method of treatment using ligand-immunogen conjugates
WO2015105973A1 (fr) * 2014-01-08 2015-07-16 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Anticorps ciblant une protéine c3d du complément déposée sur une surface cellulaire, et utilisation de celui-ci
US10035848B2 (en) 2014-01-08 2018-07-31 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Antibody targeting cell surface deposited complement protein C3d and use thereof
US11384139B2 (en) 2014-01-08 2022-07-12 The United States of Americans represented by the Secretary, Department of Health and Human Services Antibody targeting cell surface deposited complement protein C3d and use thereof

Also Published As

Publication number Publication date
GB8907310D0 (en) 1989-05-17

Similar Documents

Publication Publication Date Title
JP3443119B2 (ja) 腫瘍壊死因子結合リガンド
JP3066983B2 (ja) 膜結合ｃｄ３０抗原の蛋白質分解性開裂及び遊離を防ぐ抗ｃｄ３０抗体
Pai et al. Treatment of advanced solid tumors with immunotoxin LMB–1: an antibody linked to Pseudomonas exotoxin
JP3589459B2 (ja) 生物応答調節物質の新規な抗体運送システム
ES2579277T3 (es) Utilización combinada de un agente de bloqueo CTLA-4 y una terapia linfotóxica en el tratamiento de tumores
IL184803A (en) Purified antibodies against epha2, methods for their production, pharmaceutical compositions comprising them and use thereof in the preparation of medicaments for treating cancer
JPS60502104A (ja) α―インターフェロンに対する抗体と複合されたα―インターフェロン治療製剤
JP2024075771A (ja) 固形腫瘍を治療するためのチューブリン破壊剤を含む抗体薬物コンジュゲートの使用
JPH08505764A (ja) 腫瘍血管内皮細胞に特異的に結合するモノクローナル抗体とその利用方法
JPH06500563A (ja) 調節された浄化時間を有する修飾抗体
JPH05505823A (ja) 細胞成長抑制法およびそれに有用な組成物
JPH05505595A (ja) 二つのエフェクター機能を有する二元特異性異種抗体
US5326559A (en) Treatment of accelerated atheosclerosis with interleukin-2 receptor targeted molecules
USRE38008E1 (en) Methods for improved targeting of antibody, antibody fragments, hormones and other targeting agents, and conjugates thereof
KR101266389B1 (ko) 항 인간 테나신 단클론 항체
JP7750902B2 (ja) 抗ｃｄ３０抗体薬物複合体療法の副作用を軽減する方法
Yang et al. Pharmacokinetics and mechanism of action of a doxorubicin-monoclonal antibody 9.2. 27 conjugate directed to a human melanoma proteoglycan
WO1990011779A1 (fr) Heteroconjugues
AU616161B2 (en) Methods for improved targeting of antibody, antibody fragments, hormones and other targeting agents, and conjugates thereof
CA2366713A1 (fr) Constructions d'anticorps et de chimiokines et leur utilisation pour le traitement des maladies auto-immunes
Pietersz et al. Comparison of the biological properties of two anti-mucin-1 antibodies prepared for imaging and therapy
JPH03504854A (ja) 細胞毒素療法
EP0525570A2 (fr) Anticorps anti-idiotypiques imitant le TNF
JPS62205034A (ja) 生物活性抗腫瘍抗体による腫瘍療法
EP0467416A1 (fr) Compositions d'anticorps d'agents therapeutiques à période de demi-vie sérique prolongée

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): JP US

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB IT LU NL SE